148 related articles for article (PubMed ID: 14977566)
1. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.
Ahn J; Feng X; Patel N; Dhawan N; Reder AT
Front Biosci; 2004 May; 9():1547-55. PubMed ID: 14977566
[TBL] [Abstract][Full Text] [Related]
2. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
4. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
[TBL] [Abstract][Full Text] [Related]
5. Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha.
Subramaniam PS; Johnson HM
J Immunol; 2002 Aug; 169(4):1959-69. PubMed ID: 12165521
[TBL] [Abstract][Full Text] [Related]
6. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.
Rep MH; Schrijver HM; van Lopik T; Hintzen RQ; Roos MT; Adèr HJ; Polman CH; van Lier RA
J Neuroimmunol; 1999 Apr; 96(1):92-100. PubMed ID: 10227428
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.
Mix E; Stefan K; Höppner J; Klauer T; Zettl UK; Strauss U; Meyer-Rienecker HJ; Rolfs A
Autoimmunity; 2003 Aug; 36(5):291-305. PubMed ID: 14567559
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
11. Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma.
Larkin J; Johnson HM; Subramaniam PS
J Interferon Cytokine Res; 2000 Jun; 20(6):565-76. PubMed ID: 10888113
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
13. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
[TBL] [Abstract][Full Text] [Related]
16. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
Genç K; Dona DL; Reder AT
J Clin Invest; 1997 Jun; 99(11):2664-71. PubMed ID: 9169496
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 2 stimulation decreases IFN-gamma receptor expression in mouse RAW264.7 macrophages.
Curry H; Alvarez GR; Zwilling BS; Lafuse WP
J Interferon Cytokine Res; 2004 Dec; 24(12):699-710. PubMed ID: 15684737
[TBL] [Abstract][Full Text] [Related]
19. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
20. Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.
Inogés S; Merino J; Bandrés E; De Castro P; Subirá ML; Sánchez-Ibarrola A
Clin Exp Immunol; 1999 Mar; 115(3):521-5. PubMed ID: 10193428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
